Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
from Sanofi - Aventis Groupe https://ift.tt/tJeklui
via IFTTT
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
https://ift.tt/RTNLqsW
from Sanofi - Aventis Groupe https://ift.tt/tJeklui
via IFTTT
from Sanofi - Aventis Groupe https://ift.tt/tJeklui
via IFTTT
0 Comments
Please ,
Do not enter any kind of span link